marijuana stocks news

Aerocrine: Sales start of NIOX VERO® in Japan

Aerocrine AB (NASDAQ Stockholm: AERO) The marketing and sales efforts of Aerocrine’s FeNO measuring device NIOX VERO® was launched Sunday the 19th at an event held at the Swedish Embassy in Tokyo in the presence of the Swedish Trade Commissioner Cecilia Leiram and attended by more than 50 leading Japanese pulmonologists.

“The start of NIOX VERO® sales in Japan today follows the introduction of our new FeNO measuring device, NIOX VERO®, in the US and Europe. Current sales of our device NIOX MINO® that was launched in Japan in November 2013 has been above expectations and NIOX VERO® now joins NIOX MINO® as the only devices for FeNO measurements that are approved by PMDA for sale in Japan.” stated Torben Thölix, International Sales Director at Aerocrine.

“Aerocrine has had an excellent cooperation with Panasonic Healthcare in the joint development and manufacture of the NIOX VERO®. This is the first product based on this cooperation, now launched in Panasonic Healthcare’s home market and we are excited about getting direct feedback from the Japanese physicians attending this event” said Mats Carlson, VP at Aerocrine

“We anticipate that the NIOX VERO® will be welcomed by the Japanese physicians and patients thanks to its portability and ease to use”, said Hideaki Hoki, president of Chest M.I Inc, exclusive distributor for NIOX products in Japan.

“Aerocrine’s new portable device is an innovative Swedish designed product and a great example of what our unique Swedish medical system and its advanced approach to research and development can do to improve asthma patient’s daily life”, commented Cecilia Leiram, Swedish Trade Commissioner in Japan.

According to the World Health Organization (www.who.int) fact sheet No 206 there are about 3 million asthmatics in Japan of whom 7% have severe and 30% have moderate asthma.

Appendix: Photos from the launch event at the Swedish Embassy in Tokyo

About Aerocrine

Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX VERO® and NIOX MINO® which enables fast and reliable point-of-care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the NASDAQ Stockholm since 2007. For more information please visit www.aerocrine.com andwww.niox.com.

This information was brought to you by Cision https://news.cision.com

Contact:
Aerocrine AB
Scott Myers
Chief Executive Officer
Phone: +46 768 788 379 / +1 970-368-0336
or
Mats Carlson
VP Global Business Operations
Phone: +

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published.

You May Also Like

$AFI The U.S. Department of Agriculture (ARS) Agrees to Collaborate

The U.S. Department of Agriculture (ARS) Agrees to Collaborate and Grow Strawberries…

American Premium Water Corporation (HIPH) to Present at the Emerging Growth Conference on March 31st, 2021

American Premium Water Corp. (OTC:HIPH) to Present at the Emerging Growth Conference…

$OGRMF Receives Increased License Capacity

OrganiGram Receives Increased License Capacity  MONCTON, NEW BRUNSWICK–(Marketwired – Apr 13, 2015)…

GTEC Holdings Ltd. (GTEC) Holdings Issued Dealer’s License from Health Canada

GTEC Holdings Issued Dealer’s License from Health Canada GTEC Holdings Ltd. (TSXV:…